Custom Search Insider Trading Activity Insider Trading Activity
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Custom Search Insider Trading Activity
Updated Sep 13, 2021
Ticker
|
Company Name
|
Qty.
|
Price
|
Size ($)
|
Filing Date
|
Type
|
Δ Own
|
Own
|
Insider Names
|
Title
|
Trade Dates
|
Is Scheduled
| |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Clarus Therapeutics Holdings, Inc.
| 5.69M |
—
|
—
|
∞
| 5.69M |
Sep 9
| |||||||
Clarus Therapeutics Holdings, Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
Auspex Pharmaceuticals, Inc.
| -4.84M |
—
|
—
| -100.00% |
0
|
May 5
| |||||||
Auspex Pharmaceuticals, Inc.
| -730.00K |
$53.11 | -$38,770,300.00 | -13.12% | 4.84M |
Jan 28
| |||||||
Auspex Pharmaceuticals, Inc.
| 295.13K |
$27.73 | -$263.92 | +5.60% | 5.57M |
Jan 8
| |||||||
Auspex Pharmaceuticals, Inc.
| 50.38K |
$13.89 | -$54.61 | +0.97% | 5.27M |
Oct 9
| |||||||
Auspex Pharmaceuticals, Inc.
| 53.44K |
$12.24 | -$25.72 | +1.03% | 5.22M |
May 14
| |||||||
Auspex Pharmaceuticals, Inc.
| 53.44K |
$12.24 | -$25.72 | +1.03% | 5.22M |
May 14
| |||||||
Auspex Pharmaceuticals, Inc.
| 5.17M |
$12.00 | $1,000,008.00 |
∞
| 5.17M |
Feb 10
| |||||||
Auspex Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
Ocera Therapeutics, Inc.
| 2.44M |
$6.00 | $14,631,414.00 |
∞
| 2.44M |
Feb 6 - Jul 15
| |||||||
Ocera Therapeutics, Inc.
| 2.5M |
$6.00 | $15,000,012.00 |
∞
| 2.5M |
Apr 19 - Jul 15
| |||||||
Celator Pharmaceuticals Inc
|
0
|
—
|
—
|
—
|
0
| ||||||||
Tranzyme Inc
|
0
|
—
|
—
|
—
|
0
|
Aug 7
| |||||||
Tranzyme Inc
|
0
|
—
|
—
|
—
|
0
|
Apr 19
| |||||||
Tranzyme Inc
| 3M |
$4.00 | $3,250,000.00 | +24.10% | 15.46M |
Apr 6
| |||||||
Tranzyme Inc
|
0
|
—
|
—
|
—
|
0
| ||||||||
It looks like there's no data for these filter options. Maybe you'll be interested in these options instead. |